Literature DB >> 3185908

Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI.

J Oger1, L F Kastrukoff, D K Li, D W Paty.   

Abstract

We have serially studied immunoglobulin G secretion in vitro, natural killer cell function, and concanavalin A-induced suppression in a group of seven patients with relapsing-remitting multiple sclerosis. In two patients, the development of a large clinically asymptomatic MRI lesion was accompanied by reductions in natural killer cell function, immunoglobulin G secretion in vitro (after pokeweed mitogen stimulation), and concanavalin A-induced suppression without parallel change in lymphocyte markers. We did not see this type of change in matched controls nor in stable multiple sclerosis studied serially. When clinical attacks appeared, there was no significant change in immune function. We conclude that changes in immune function correlate well with the activity of the disease as recognized by MRI. We suspect that decreased natural killer cell function, immunoglobulin G secretion in vitro, and concanavalin A-induced suppression are secondary to the large lesions recognized by MRI.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3185908     DOI: 10.1212/wnl.38.11.1739

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 2.  The role of natural killer cells in curbing neuroinflammation.

Authors:  Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2007-09-29       Impact factor: 3.478

Review 3.  Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials.

Authors:  P S Sørensen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

4.  Degradation of human myelin in vitro by leucocytes from patients with multiple sclerosis.

Authors:  S J Owen; C M Watson; A N Davison
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

Authors:  A Salmaggi; A Dufour; M Eoli; E Corsini; L La Mantia; G Massa; A Nespolo; C Milanese
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

6.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

7.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

8.  Imaging of human T-lymphotropic virus type I-associated chronic progressive myeloneuropathies.

Authors:  F Alcindor; R Valderrama; M Canavaggio; H Lee; A Katz; C Montesinos; R E Madrid; R R Merino; P A Pipia
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

9.  CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.

Authors:  J Elkins; J Sheridan; L Amaravadi; K Riester; K Selmaj; B Bielekova; E Parr; G Giovannoni
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-01-22

10.  The role of natural killer cells in multiple sclerosis and their therapeutic implications.

Authors:  Coralie Chanvillard; Raymond F Jacolik; Carmen Infante-Duarte; Ramesh C Nayak
Journal:  Front Immunol       Date:  2013-03-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.